Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Activated Leukocyte Cell Adhesion Molecule (ALCAM) Regulate Myeloma Cancer Stem Cell Mediated Myelomagenesis and Chemoresistance

Yuhuan Zheng, Hongmei Luo, Dan Zhang, Fangfang Wang

Blood (2018) 132 (Supplement 1): 3190.

https://doi.org/10.1182/blood-2018-99-111740

Published: 2018

Journal Articles

Platelets Promote Breast Cancer Metastasis By Reprogramming Tumor Cells to Produce IL-8

Kelly Elizabeth Johnson, PhD, Kellie R Machlus, PhD, Saleh El-Husayni, Rajesh Kulenthirarajan, Jodi A Forward, Joseph E Italiano, Jr., PhD, Elisabeth M. Battinelli, MD PhD

Blood (2015) 126 (23): 2233.

https://doi.org/10.1182/blood.V126.23.2233.2233

Published: 2015

Journal Articles

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Blood (2014) 124 (21): 3414.

https://doi.org/10.1182/blood.V124.21.3414.3414

Published: 2014

Journal Articles

Aberrant Activation of Epidermal Growth Factor Receptor in MPN May Respond to the Kinase Inhibitor Gefitinib

Debora A Casolari, PhD, Diana G Iarossi, BSc (Hons), Carolyn M Butcher, MMedSc(Hons), Sarah C Bray, PhD, Wendy T Parker, PhD, Chris N Hahn, PhD, Susan Branford, PhD, Peter Bardy, MD, Ian D Lewis, MBBS, PhD, Hamish S Scott, PhD, Steven W Lane, MD PhD, David M Ross, MBBS, PhD FRACP, FRCPA, Richard J D'Andrea, PhD

Blood (2014) 124 (21): 1882.

https://doi.org/10.1182/blood.V124.21.1882.1882

Published: 2014

Journal Articles

Relationship of Epidermal Growth Factor to Cyclosporine-Assocated Magnesium Wasting and Clinical Outcomes Post-Allogeneic Hematopoietic Cell Transplantation

Fiona C. He, MD, Michael R. Verneris, MD, Sarah A. Cooley, MD MS, Bruce R. Blazar, MD, Margaret L. MacMillan, MD, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Shernan G. Holtan, MD

Blood (2014) 124 (21): 3914.

https://doi.org/10.1182/blood.V124.21.3914.3914

Published: 2014

Journal Articles

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Hamid Sayar, MD, MSc, Magdalena Czader, MD, PhD, Chirag Amin, MD, Mary Cangany, Bsc, Larry D Cripe, MD

Blood (2013) 122 (21): 5037.

https://doi.org/10.1182/blood.V122.21.5037.5037

Published: 2013

Journal Articles

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Elodie Lainey, Marie Sebert, Cyrielle Bouteloup, Carole Leroy, Sylvain Thepot, Maximilien Tailler, Lionel Ades, Claude Gardin, MD, Guido Kroemer, MD, PhD, Pierre Fenaux, MD, PhD, Simone Boehrer, MD, PhD

Blood (2011) 118 (21): 2564.

https://doi.org/10.1182/blood.V118.21.2564.2564

Published: 2011

Journal Articles

Epidermal Growth Factor Receptor Expression and Activity In Acute Myeloid Leukemia

Arja ter Elst, Steven M. Kornblau, MD, Frank jg Scherpen, Yi Hua Qiu, MD, Nianxiang Zhang, Kevin R Coombes, Evelina S. De Bont, MD, PhD

Blood (2010) 116 (21): 3144.

https://doi.org/10.1182/blood.V116.21.3144.3144

Published: 2010

Journal Articles

Factor XII Stimulates ERK1/2 and Akt through uPAR, Integrins, and the EGFR to Initiate Angiogenesis.

Gretchen Larusch, Fakhri Mahdi, Zia Shariat-Madar, PhD, Gregory N Adams, Robert Sitrin, Wanming Zhang, Keith R. McCrae, MD, Alvin H. Schmaier, MD

Blood (2009) 114 (22): 3040.

https://doi.org/10.1182/blood.V114.22.3040.3040

Published: 2009

Journal Articles

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Simone Boehrer, MD, PhD, Lorenzo Galluzzi, phD, Lionel Ades, MD, Celine Fouassier, Claude Gardin, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2009) 114 (22): 3813.

https://doi.org/10.1182/blood.V114.22.3813.3813

Published: 2009

Journal Articles

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma

Lauren C. Harshman, M.D., Calvin J. Kuo, M.D., Ph.D., Bryan Y. Wong, M.D., Ph.D., Nicholas J. Vogelzang, M.D., Sandy Srinivas, M.D.

Blood (2008) 112 (11): 3453.

https://doi.org/10.1182/blood.V112.11.3453.3453

Published: 2008

Journal Articles

Pharmacological Inhibition of EGFR Signaling Enhances G-CSF Induced Hematopoietic Stem Cell Mobilization.

Marnie A. Ryan, PhD, Ellen Xing, David Schleimer, Kalpana Nattamai, Deidre Daria, Wei Liu, MD, MS, Michael Jansen, MS, PhD, Nancy Ratner, Timothy Le Cras, Gary Van Zant, PhD, Yi Zheng, PhD, Hartmut Geiger, PhD

Blood (2008) 112 (11): 2337.

https://doi.org/10.1182/blood.V112.11.2337.2337

Published: 2008

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Simone Boehrer, MD, Lionel Ades, MD, Thorsten Braun, MD, Lorenzo Galluzzi, Jennifer Grosjean, Claire Fabre, MD, Genevieve Le Roux, Claude Gardin, MD, Antoine Martin, MD, Stephane de Botton, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2007) 110 (11): 399.

https://doi.org/10.1182/blood.V110.11.399.399

Published: 2007

Journal Articles

Syk Is a New Target for AML Differentiation.

Cynthia K. Hahn, BA, Kenneth N. Ross, PhD, Rose M. Kakoza, BA, Steven A. Carr, PhD, Jinyan Du, PhD, Shao-En Ong, PhD, Todd R. Golub, MD, Kimberly Stegmaier, MD

Blood (2007) 110 (11): 209.

https://doi.org/10.1182/blood.V110.11.209.209

Published: 2007

Journal Articles

Human Tissue Transglutaminase Activity Is Inhibited by Protein Kinase Inhibitors: Potential Therapeutic Implication for Hematological Disorders.

Thung-S. Lai, PhD, Yusha Liu, Ho Young Lee, Eric Toone, Ph.D., Charles S. Greenberg, M.D.

Blood (2006) 108 (11): 1614.

https://doi.org/10.1182/blood.V108.11.1614.1614

Published: 2006

Journal Articles

The EGFR-Inhibitor Erlotinib Induces Apoptosis in Neoplastic Cells of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), an Effect Determined by the Expression Level of Nucleophosmin (NPM).

Simone Boehrer, MD, PhD, Lionel Ades, MD, Claire Fabre, MD, Pierre Fenaux, MD, PhD, Guido Kroemer, MD, PhD

Blood (2006) 108 (11): 856.

https://doi.org/10.1182/blood.V108.11.856.856

Published: 2006

Journal Articles

Rapid Wnt/β-Catenin Pathway Activation by Tobacco Smoke Modulates Cyclooxygenase-2 Expression in Cardiac Microvascular Endothelial Cells.

Silvia S. Barbieri, PhD, Dawn Ip, BS, Louise R. Howe, PhD, Babette B. Weksler, MD

Blood (2005) 106 (11): 3697.

https://doi.org/10.1182/blood.V106.11.3697.3697

Published: 2005

Journal Articles

Effects of EGF-R on Signal Transduction and Anti-Apoptotic Cascades in Hematopoietic Cells: EGF-R Activates Multiple Signal Transduction Cascades Which Result in the Prevention of Apoptosis in the Absence of Autocrine Cytokines.

John G. Shelton, B.S., Linda S. Steelman, M.S., Martin McMahon, Ph.D., James A. McCubrey, Ph.D.

Blood (2004) 104 (11): 1264.

https://doi.org/10.1182/blood.V104.11.1264.1264

Published: 2004

NARROW

Activated Leukocyte Cell Adhesion Molecule (ALCAM) Regulate Myeloma Cancer Stem Cell Mediated Myelomagenesis and Chemoresistance

Platelets Promote Breast Cancer Metastasis By Reprogramming Tumor Cells to Produce IL-8

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Aberrant Activation of Epidermal Growth Factor Receptor in MPN May Respond to the Kinase Inhibitor Gefitinib

Relationship of Epidermal Growth Factor to Cyclosporine-Assocated Magnesium Wasting and Clinical Outcomes Post-Allogeneic Hematopoietic Cell Transplantation

Pilot Study Of Erlotinib In Patients With Acute Myeloid Leukemia

Erlotinib Antagonizes Efflux Via ABC Transporters and Decreases P-Gp Cell Surface Expression by Inhibiting SRC Kinase and mTOR Pathways in Acute Myeloid Leukemia (AML)

Epidermal Growth Factor Receptor Expression and Activity In Acute Myeloid Leukemia

Factor XII Stimulates ERK1/2 and Akt through uPAR, Integrins, and the EGFR to Initiate Angiogenesis.

Increased Proliferation Induced by Constitutive Activation of the Src-Kinase Lyn and Aberrant mTOR Signaling in AML Is Abrogated by the EGFR-Inhibitor Erlotinib.

Increased Hemoglobin Associated with VEGF Inhibitors in Advanced Renal Cell Carcinoma

Pharmacological Inhibition of EGFR Signaling Enhances G-CSF Induced Hematopoietic Stem Cell Mobilization.

The EGFR-Inhibitor Erlotinib Induces Differentiation, Cell Cycle Arrest and Apoptosis in EGFR-Negative Cells of MDS and AML.

Syk Is a New Target for AML Differentiation.

Human Tissue Transglutaminase Activity Is Inhibited by Protein Kinase Inhibitors: Potential Therapeutic Implication for Hematological Disorders.

The EGFR-Inhibitor Erlotinib Induces Apoptosis in Neoplastic Cells of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML), an Effect Determined by the Expression Level of Nucleophosmin (NPM).

Rapid Wnt/β-Catenin Pathway Activation by Tobacco Smoke Modulates Cyclooxygenase-2 Expression in Cardiac Microvascular Endothelial Cells.

Effects of EGF-R on Signal Transduction and Anti-Apoptotic Cascades in Hematopoietic Cells: EGF-R Activates Multiple Signal Transduction Cascades Which Result in the Prevention of Apoptosis in the Absence of Autocrine Cytokines.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only